Heart Disease & Cardiology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)

This Phase 3 trial is exploring whether injecting botulinum toxin during cardiac surgery can prevent atrial fibrillation, a common and serious heart rhythm problem after surgery. If the treatment works, it may lower the chances of complications and reduce hospital stays for patients undergoing heart operations. The study is currently recruiting 220 participants in France, with results expected in the future.

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

This Phase 4 trial is testing semaglutide, a medication, in adults who have a type of heart failure linked to obesity. By focusing on weight loss, the treatment aims to improve symptoms for patients with this particular heart failure condition. The trial is enrolling by invitation at a site in the United States, and results are anticipated soon.

Evalutation of a Hybrid Care Pathway With Remote MONitoring for Heart Failure

This study is looking at a new way to care for heart failure patients by combining in-person visits with daily health monitoring from home. The goal is to help patients stay out of the hospital and spend more time at home by sending daily health data to their medical team. The trial is ongoing in seven hospitals across the Netherlands and includes about 6000 patients receiving routine care.

Polyamine Treatment in Elderly Patients With Coronary Artery Disease

Researchers are testing an oral treatment called spermidine in elderly patients with coronary artery disease to see if it can improve heart function and reduce inflammation. This Phase 2 trial is taking place at a single center in Denmark and is currently active but not recruiting new participants. If successful, it could offer a simple new option for managing heart disease in older adults.

Continuation of the nuMoM2b Heart Health Study

This observational study follows women who have been pregnant to better understand their long-term risk of heart disease. The aim is to find ways to predict and prevent cardiovascular problems specifically in women, which could lead to improved health care strategies. The study is enrolling by invitation at multiple locations in the United States and includes ongoing long-term follow-up.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.